« We remain encouraged that there is no degradation in Prima’s prosthetic visual performance, given some external speculation that advanced Dry-AMD could eventually provoke atrophic damage to the retinal ganglion cells (on which the Prima system relies for providing the patient’s prosthetic vision). »
« While we have pushed back our potential launch forecast to H124 (from H223), after tweaking our market growth assumptions, we now obtain a higher equity valuation of €143.3m (versus €138.0m previously). »
“Pixium expects to be sufficiently funded through the end of 2022, which we believe removes a near-term funding gap overhang and may result in market participants placing greater attention on the Prima commercial opportunity and PRIMAvera data inflection point, rather than funding needs.”